NewGenIvf Group Ltd

NewGenIvf provides fertility treatments, primarily focusing on in vitro fertilization (IVF) services and fertility referral services. The company operates three clinics: one in Thailand, one in Cambodia, and one in Kyrgyzstan. Its IVF treatment service includes traditional IVF and egg donation. For the period ended December 31, 2025, approximately 82.6% of NewGenIvf's revenue came from IVF treatments, while for the year ended December 31, 2024, this figure was 100%. These services primarily involve conventional IVF/intracytoplasmic sperm injection (ICSI) and embryo transfer. The company also utilizes MicroSort technology to assist clients with family balancing and avoiding certain gender-related hereditary diseases. Revenue from IVF treatment is recognized when the treatment is completed in the clinic, evidenced by a written IVF report indicating successful embryo implantation. NewGenIvf also generates revenue from fertility referral services in Kyrgyzstan. For the period ended December 31, 2025, approximately 17.4% of its revenue was from these services, compared to Nil % for the year ended December 31, 2024. For customers interested in surrogacy services in Kyrgyzstan, NewGenIvf refers them to agents and receives a referral commission, with the surrogacy mother services provided independently by the agents. For the years ended December 31, 2024 and 2025, NewGenIvf's revenue was US$5,433,375 and US$4,726,433, and its net income/(loss) was US$(474,101) and US$8,763,979, respectively.